Group
TRK targeting TKI
Group Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Tyrosine Kinase Inhibitors (TKIs) |
| Mechanism of Action | Pan-TRK inhibitor |
| Drugs in group | Larotrectinib |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Uncertain/possibly no radiosensitization (TrkA inhibition was radioprotective in some models) (Jarboe et al., Radiotherapy and Oncology, 2012; Hassiepen et al., Cancers, 2021), though evidence is limited.
The data above refer to patients treated with TRK targeting TKI as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.